Início › Câncer de Pulmão de Não Pequenas Células › Ohio

Ensaios clínicos de Câncer de Pulmão de Não Pequenas Células em Ohio

121 estudos para Câncer de Pulmão de Não Pequenas Células estão buscando participantes em locais em Ohio.

Cidades em Ohio

Texto oficial do estudo (Inglês)

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

Cleveland Clinic Akron General, Akron
Strecker Cancer Center-Belpre, Belpre
Aultman Health Foundation, Canton
e mais 33

RecrutandoFase 3

Idades 18 e acima · Todos os sexos · Atualizado em 2 de out. de 2026 · NCT04267848

A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

University of Cincinnati Medical Center ( Site 0119), Cincinnati

RecrutandoFase 3

Idades 18 e acima · Todos os sexos · Atualizado em 2 de out. de 2026 · NCT06623422

A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment

Ohio State University Comprehensive Cancer Center, Columbus

RecrutandoFase 2

Idades 18 e acima · Todos os sexos · Atualizado em 2 de out. de 2026 · NCT07293247

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

The Cleveland Clinic Taussig Cancer Center, Cleveland

RecrutandoFase 1/2

Idades 12 e acima · Todos os sexos · Atualizado em 2 de out. de 2026 · NCT04585750

A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

University Hospitals Cleveland Medical Center, Cleveland

RecrutandoFase 1

Idades 18 e acima · Todos os sexos · Atualizado em 2 de out. de 2026 · NCT06465069

A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Local Institution - 0176, Columbus

RecrutandoFase 2

Idades 18 e acima · Todos os sexos · Atualizado em 2 de out. de 2026 · NCT07680764

Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors

Exelixis Clinical Site #10, Cleveland

RecrutandoFase 1

Idades 18 e acima · Todos os sexos · Atualizado em 1 de out. de 2026 · NCT05176483

Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial

ProMedica Flower Hospital, Sylvania

RecrutandoFase 3

Idades 18 e acima · Todos os sexos · Atualizado em 1 de out. de 2026 · NCT07388524

Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

Aultman Health Foundation, Canton
Miami Valley Hospital South, Centerville
Ohio State University Comprehensive Cancer Center, Columbus
e mais 4

RecrutandoFase 3

Idades 18 e acima · Todos os sexos · Atualizado em 1 de out. de 2026 · NCT06498635

A Platform Study in Non-Small Cell Lung Cancer (NSCLC)

Research Site, Cleveland

RecrutandoFase 1/2

Idades 18 e acima · Todos os sexos · Atualizado em 1 de out. de 2026 · NCT06996782

A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors

ALX Center 10, Columbus

RecrutandoFase 1

Idades 18 e acima · Todos os sexos · Atualizado em 30 de set. de 2026 · NCT07085091

A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)

Akron General Medical Center, Akron
The Christ Hospital, Cincinnati
University Hospitals Cleveland Medical Center, Cleveland
e mais 2

RecrutandoFase 3

Idades 18 e acima · Todos os sexos · Atualizado em 30 de set. de 2026 · NCT07361497

A Phase 1, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Peptide Drug Conjugate (PDC), TS-104, as a Monotherapy in Subjects With Select Advanced Solid Tumors

Site 06, Maumee

RecrutandoFase 1

Idades 18 e acima · Todos os sexos · Atualizado em 30 de set. de 2026 · NCT07814248

A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)

Local Institution - 0383, Cincinnati

RecrutandoFase 3

Idades 18 e acima · Todos os sexos · Atualizado em 30 de set. de 2026 · NCT07361510

Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC

University of Cincinnati Cancer Center, Cincinnati
The Ohio State University, Columbus

RecrutandoFase 3

Idades 18 e acima · Todos os sexos · Atualizado em 30 de set. de 2026 · NCT06765109

Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations

The Mark H Zangmeister Center /ID# 272502, Columbus

RecrutandoFase 1/2

Idades 18 e acima · Todos os sexos · Atualizado em 29 de set. de 2026 · NCT06772623

Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)

TriHealth Cancer & Blood Institute Research, Cincinnati
Taylor Cancer Research Center, Maumee

RecrutandoFase 3

Idades 18 e acima · Todos os sexos · Atualizado em 29 de set. de 2026 · NCT06881784

A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)

University Hospitals Seidman Cancer Center at UH Avon Health Center, Avon
Oncology_Hematology Care Clinical Trials,LLC, Cincinnati
Oncology_Hematology Care Clinical Trials,LLC, Cincinnati
e mais 5

RecrutandoFase 3

Idades 18 e acima · Todos os sexos · Atualizado em 28 de set. de 2026 · NCT07144280

Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Aultman Hospital, Canton
Aultman Medical Group Hematology and Oncology, Canton
Oncology Hematology Care Clinical Trials, Cincinnati
e mais 7

RecrutandoFase 3

Idades 18 e acima · Todos os sexos · Atualizado em 25 de set. de 2026 · NCT07222566

A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)

Dayton Physician's Network, Dayton

RecrutandoFase 3

Idades de 18 a 100 · Todos os sexos · Atualizado em 25 de set. de 2026 · NCT05920356

Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing

The Ohio State University Comprehensive Cancer Center, Columbus

RecrutandoEstudo observacional

Idades 18 e acima · Todos os sexos · Atualizado em 25 de set. de 2026 · NCT04981119

This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.

University Hospitals Seidman Cancer Center at UH Avon Health Center, Avon
University Hospitals Cleveland Medical Center, Cleveland
University Hospitals Seidman Cancer Center at UH Mentor Health Center, Mentor
e mais 1

RecrutandoFase 3

Idades 18 e acima · Todos os sexos · Atualizado em 25 de set. de 2026 · NCT06758401

A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Cincinnati Veterans Affairs Medical Center, Cincinnati

RecrutandoFase 2

Idades 18 e acima · Todos os sexos · Atualizado em 25 de set. de 2026 · NCT06667076

A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)

University Hospitals Cleveland Medical Center, Cleveland

RecrutandoFase 2

Idades 18 e acima · Todos os sexos · Atualizado em 25 de set. de 2026 · NCT06667908

A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer

Research Site, Canton

RecrutandoFase 3

Idades 18 e acima · Todos os sexos · Atualizado em 25 de set. de 2026 · NCT06868277

Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

Aultman Hospital, Canton
Miami Valley Hospital South, Centerville
Fairview Hospital, Cleveland
e mais 4

RecrutandoFase 3

Idades 18 e acima · Todos os sexos · Atualizado em 24 de set. de 2026 · NCT06890598

Pan-tumor MRD Study

Gabrail Cancer Center, Canton
Taylor Cancer Research Center, Maumee

RecrutandoEstudo observacional

Idades 18 e acima · Todos os sexos · Atualizado em 24 de set. de 2026 · NCT06605404

Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change

Ohio State University Comprehensive Cancer Center, Columbus

RecrutandoFase 2

Idades 18 e acima · Todos os sexos · Atualizado em 24 de set. de 2026 · NCT03191149

A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%

Local Institution - 0486, Centerville
University of Cincinnati Medical Center, Cincinnati
Local Institution - 0519, Elyria
e mais 1

RecrutandoFase 3

Idades 18 e acima · Todos os sexos · Atualizado em 23 de set. de 2026 · NCT06561386

Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations

Research Site, Cincinnati
Research Site, Maumee
Research Site, Toledo

RecrutandoFase 3

Idades 18 e acima · Todos os sexos · Atualizado em 23 de set. de 2026 · NCT06357533

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors

Cleveland Clinic, Cleveland
Local Institution - 0102, Columbus

RecrutandoFase 1/2

Idades 18 e acima · Todos os sexos · Atualizado em 23 de set. de 2026 · NCT06618287

Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer

Research Site, Cleveland

RecrutandoFase 2

Idades de 18 a 95 · Todos os sexos · Atualizado em 23 de set. de 2026 · NCT05061550

Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer

Gabrail Cancer Center Research, Canton
The Christ Hospital Cancer Center, Cincinnati
University of Cincinnati Medical Center, Cincinnati
e mais 5

RecrutandoFase 2/3

Idades 18 e acima · Todos os sexos · Atualizado em 22 de set. de 2026 · NCT06712316

A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Mercy Health - Perrysburg Cancer Center /ID# 270536, Perrysburg
Genesis Healthcare System /ID# 273361, Zanesville

RecrutandoFase 2

Idades 18 e acima · Todos os sexos · Atualizado em 22 de set. de 2026 · NCT06568939

Pulmonary Rehabilitation in Advanced Lung Cancer Survivors

University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland

RecrutandoFase 2

Idades 18 e acima · Todos os sexos · Atualizado em 22 de set. de 2026 · NCT07104630

Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)

University Hospitals Cleveland Medical Center, Cleveland
The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive C, Columbus

RecrutandoFase 2/3

Idades 18 e acima · Todos os sexos · Atualizado em 22 de set. de 2026 · NCT07100080

Personalized Cancer Vaccine (PCV) Strategy in Patients With Solid Tumors and Molecular Residual Disease

Ohio State University, Columbus

RecrutandoFase 1

Idades 18 e acima · Todos os sexos · Atualizado em 21 de set. de 2026 · NCT06529822

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

Research Site, Cincinnati

RecrutandoFase 3

Idades 18 e acima · Todos os sexos · Atualizado em 18 de set. de 2026 · NCT06692738

Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1

Clinical Study Sites, Cincinnati
Clinical Study Site, Cleveland
Clinical Study Sites, Columbus
e mais 1

RecrutandoFase 3

Idades 18 e acima · Todos os sexos · Atualizado em 18 de set. de 2026 · NCT06767514

A Study of Navlimetostat (BMS-986504) Alone or in Combination With Izalontamab Brengitecan in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion or MTAP Loss (MountainTAP-9)

Gabrail Cancer Center, Canton

RecrutandoFase 2

Idades 18 e acima · Todos os sexos · Atualizado em 18 de set. de 2026 · NCT06855771

Fonte: ClinicalTrials.gov, dados obtidos em 5 de out. de 2026. Cada estudo define seus próprios critérios de elegibilidade; a equipe do estudo decide quem pode participar.